gefitinib

Ponatinib & Molecular Response in Leukemia | Latest Research

by

Advanced Therapy Shows Promise for Difficult-to-Treat Leukemia Cases Table of Contents Advanced Therapy Shows Promise for Difficult-to-Treat Leukemia Cases The Evolution of Treatment for Ph+ ALL Extending Treatment Beyond Initial Induction: A New Analysis Impact on Long-Term Outcomes and Transplantation Safety Considerations and Future Directions Ponatinib Demonstrates Efficacy and Improved Safety Profile in Philadelphia Chromosome-Positive … Read more

Immunotherapy Insights and Research in Endometrial Cancer

by

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A. Matulonis, MD: Hello. I’m Dr Ursula Matulonis. Welcome to season 2 of the Medscape InDiscussion Endometrial Cancer podcast series. I am honored to have as … Read more

Weill Cornell’s Leonard Noted for His ASH List, Patient Care

by

John Leonard, MD John Leonard, MD, of Weill Cornell Medicine, New York City, has built a devoted following for his “Leonard List” — previews of research to be presented at annual American Society of Hematology (ASH) meetings that are held every December. For example, in November 2024, in the days leading up to ASH 2025, … Read more

Vasculitis Patients Need Multiple COVID Vaccine Boosters

by

People with vasculitis may need at least three or four vaccinations for COVID-19 before they start to show an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, new research has suggested. In a longitudinal retrospective study, serum antibody neutralization against the Omicron variant of the virus and its descendants was found to … Read more

Baricitinib Shows Promise in Polymyalgia Rheumatica

by

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the 18 patients randomly assigned to the oral Janus kinase (JAK) inhibitor baricitinib, 14 achieved a C-reactive protein PMR activity score (CRP PMR-AS) of 10 or less after 12 weeks of … Read more